期刊
NATURE MEDICINE
卷 26, 期 3, 页码 430-+出版社
NATURE PORTFOLIO
DOI: 10.1038/s41591-020-0753-3
关键词
-
资金
- NIAID [UM1AI100663, UM1AI144462, AI125068, AI048240, K99AI145762, AI113867]
- Koch Institute Support (core) grant from National Cancer Institute [P30-CA14051]
- Ragon Institute of MGH, MIT and Harvard
- International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Consortium (NAC) and Center
- Collaboration for AIDS Vaccine Discovery
Adjuvants are central to the efficacy of subunit vaccines. Aluminum hydroxide (alum) is the most commonly used vaccine adjuvant, yet its adjuvanticity is often weak and mechanisms of triggering antibody responses remain poorly understood. We demonstrate that site-specific modification of immunogens with short peptides composed of repeating phosphoserine (pSer) residues enhances binding to alum and prolongs immunogen bioavailability. The pSer-modified immunogens formulated in alum elicited greatly increased germinal center, antibody, neutralizing antibody, memory and long-lived plasma cell responses compared to conventional alum-adsorbed immunogens. Mechanistically, pSer-immunogen:alum complexes form nanoparticles that traffic to lymph nodes and trigger B cell activation through multivalent and oriented antigen display. Direct uptake of antigen-decorated alum particles by B cells upregulated antigen processing and presentation pathways, further enhancing B cell activation. These data provide insights into mechanisms of action of alum and introduce a readily translatable approach to significantly improve humoral immunity to subunit vaccines using a clinical adjuvant. Alum coupled to protein immunogens via site-specific phosphoserine-containing linkers enhances long-lived B cell responses and can selectively direct antibodies toward protective neutralizing epitopes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据